How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

404 results for

Quinupristin-Dalfopristin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis (PubMed)

/dalfopristin. Teicoplanin is not available in some countries (e.g. the USA). Tigecycline can only be given intravenously. Quinupristin/dalfopristin is ineffective against Enterococcus faecalis and there is only low-quality evidence to support its efficacy in the treatment of peritonitis. Effective newer antibiotics against drug-resistant Gram-negative bacteria are lacking. Polymyxins can be considered, but evidence on its efficacy is limited. In this review, we will discuss the potential use of newer (...) be used due to allergy and/or non-susceptibility, there is increasing evidence that linezolid and daptomycin are the drugs of choice. It is reasonable to start linezolid orally or intravenously, but subsequent dose reduction may be necessary in case of myelosuppression. Daptomycin can be given intravenously or intraperitoneally and has excellent anti-biofilm activity. Other treatment options for drug-resistant Gram-positive bacterial peritonitis include teicoplanin, tigecycline and quinupristin

Full Text available with Trip Pro

2016 Clinical kidney journal

62. Novel chromosome-encoded erm(47) determinant responsible for constitutive MLSB resistance in Helcococcus kunzii. (PubMed)

of a novel gene, named erm(47), encoding a protein sharing 44%-48% amino acid identity with known Erm methylases. In both S. aureus and S. agalactiae, the introduction of pAT29Ωerm(47) conferred a significant increase (≥16-fold) in MICs of all macrolides and lincosamides tested, as well as a 4-fold increase in MICs of quinupristin (streptogramin B), confirming the MLSB resistance. The TSS identification revealed the presence of a short leader peptide, potentially implicated in a translational attenuation

Full Text available with Trip Pro

2016 Journal of Antimicrobial Chemotherapy

64. Vancomycin resistant enterococci in urine cultures: Antibiotic susceptibility trends over a decade at a tertiary hospital in the United Kingdom (PubMed)

near zero to 40%. Ampicillin resistance fluctuated between 50% and 90%. Low resistance was observed for linezolid and quinupristin/dalfopristin. Female sex and inpatient status were identified as risk factors for vancomycin resistance.The incidence of vancomycin resistance among urinary isolates was stable over the last decade. Although resistance to nitrofurantoin has increased, it still serves as an appropriate first choice in uncomplicated urinary tract infection caused by vancomycin-resistant

Full Text available with Trip Pro

2016 Investigative and clinical urology

65. Domperidone for Chronic Nausea and Vomiting

(Anzemet®), dronabinol (Marinol®), droperidol (Inapsine®) Anti-infective agents: erythromycin (such as E.E.S.®, E-Mycin®, Ilotycin® , Pediazole®, Akne-mycin®), clarithromycin (Biaxin®), troleandomycin (TAO®), norfloxacin (Ciproxin®, Noroxin®), quinine sulfate, quinupristin and dalfopristin (Synercid®), pentamidine (Nebupent®, Pentacarinat®, Pentam®), sparfloxacin (Zagam®), grepafloxacin (Raxar®), azithromycin (Zithromax®), ofloxacin (Floxin®). Levofloxacin (Levaquin®) Anti-Fungal Agents: fluconazole

2015 Clinical Trials

66. Human health risks associated with antimicrobial-resistant enterococci and Staphylococcus aureus on poultry meat. (PubMed)

and transmission of multidrug-resistant E. faecalis lineages such as sequence type ST16. Enterococcus faecium lineages occurring in poultry meat products are distantly related to those causing hospital-acquired infections but may act as donors of quinupristin/dalfopristin resistance and other resistance determinants of clinical interest to the human gut microbiota. Ingestion of poultry meat contaminated with S. aureus may lead to food poisoning. However, antimicrobial resistance in the toxin-producing strains

Full Text available with Trip Pro

2015 Clinical Microbiology and Infection

67. Treatment of Calcific Tendinitis of the Rotator Cuff

(e.g. pimozide, sertindole, olanzapine, quetiapine, zotepine, tropisetrone, dolasetron), antibiotics such as quinopristin/dalfopristin. Any history of prior allergic/hypersensitivity reactions related to the study medication Knowledge of an ongoing pregnancy (Fertile women not using contraception and who are uncertain whether they are pregnant or not will have to perform a pregnancy test) Nursing women Contacts and Locations Go to Information from the National Library of Medicine To learn more

2015 Clinical Trials

68. When sepsis persists: a review of MRSA bacteraemia salvage therapy. (PubMed)

are the only two antibiotics approved by the US FDA for the treatment of patients with MRSAB as monotherapy, the employment of novel strategies is required to effectively treat patients with persistent MRSAB and these may frequently involve combination drug therapy. Treatment strategies that are reviewed in this manuscript include vancomycin combined with a β-lactam, daptomycin-based therapy, ceftaroline-based therapy, linezolid-based therapy, quinupristin/dalfopristin, telavancin, trimethoprim

Full Text available with Trip Pro

2015 Journal of Antimicrobial Chemotherapy

69. Prevalence, species distribution and antimicrobial resistance patterns of methicillin-resistant staphylococci in Lithuanian pet animals (PubMed)

isolates (20.0 %; CI 95 % 13.5-28.6) were obtained from the vagina of female dogs (n = 105) (Group B). All isolates carried the mecA gene. Twelve MRS species were isolated of which S. pseudintermedius was the most common (18/42) followed by S. haemolyticus (8/42) and S. lentus (4/42). MRSA was not found. All MRS strains were susceptible to vancomycin, linezolid, daptomycin and quinupristin/dalfopristin. Resistance to tetracycline (16/21), clindamycin (15/21) and erythromycin (14/21) was the most common

Full Text available with Trip Pro

2015 Acta veterinaria Scandinavica

70. Meta-analysis of Randomized Controlled Trials of Vancomycin for the Treatment of Patients With Gram-Positive Infections: Focus on the Study Design (PubMed)

with linezolid, daptomycin, quinupristin-dalfopristin, tigecycline, ceftaroline, ceftobiprole, telavancin, teicoplanin, iclaprim, and dalbavancin were included in the meta-analysis. Individual antibiotics were as effective as vancomycin, except for linezolid, which was more effective than vancomycin for the treatment of skin and soft tissue infections (odds ratio [OR], 1.61; 95% confidence interval [CI], 1.07-2.43). Comparators were as effective as vancomycin in the intent-to-treat population (OR, 1.08; 95

Full Text available with Trip Pro

2012 EvidenceUpdates

72. Molecular Characterization of Vancomycin Resistant Enterococcus faecium Strains Isolated From Carriage and Clinical Samples in a Tertiary Hospital, Turkey. (PubMed)

by biochemical tests and the API-20 Strep kit. Susceptibility testing was performed using disc-diffusion and broth-dilution methods. PFGE was used for molecular typing of the VREfm strains. The vancomycin resistance and virulence genes were amplified by two-step multiplex PCR. All 55 VREfm isolates were resistant to penicillin G, ampicillin and high-level gentamicin but were susceptible to quinupristin/dalfopristin and linezolid. Multiplex PCR analysis indicated that all isolates harboured vanA and that 41

Full Text available with Trip Pro

2015 Journal of Medical Microbiology

73. Potential for reduction of streptogramin A resistance revealed by structural analysis of the VatA acetyltransferase. (PubMed)

Potential for reduction of streptogramin A resistance revealed by structural analysis of the VatA acetyltransferase. Combinations of group A and B streptogramins (i.e., dalfopristin and quinupristin) are "last-resort" antibiotics for the treatment of infections caused by Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Resistance to streptogramins has arisen via multiple mechanisms, including the deactivation

Full Text available with Trip Pro

2014 Antimicrobial Agents and Chemotherapy

74. Characterization of methicillin-resistant Staphylococcus sciuri isolates from industrially raised pigs, cattle and broiler chickens. (PubMed)

-wild-type (NWT) for gentamicin, penicillin, tiamulin, clindamycin and quinupristin/dalfopristin. The frequency of NWT isolates for fusidic acid and trimethoprim ranged between 78% and 87%. PFGE analysis allowed distinction between two major clusters. Most isolates tested by microarray carried erm and tet genes. Virulence genes were also detected, including an isa gene encoding an immune-evasion factor and the hsdS2 gene encoding a site-specific deoxyribonuclease.This study shows that multiresistant

Full Text available with Trip Pro

2014 Journal of Antimicrobial Chemotherapy

75. Synergy of streptogramin antibiotics occurs independently of their effects on translation. (PubMed)

Synergy of streptogramin antibiotics occurs independently of their effects on translation. Streptogramin antibiotics are divided into types A and B, which in combination can act synergistically. We compared the molecular interactions of the streptogramin combinations Synercid (type A, dalfopristin; type B, quinupristin) and NXL 103 (type A, flopristin; type B, linopristin) with the Escherichia coli 70S ribosome by X-ray crystallography. We further analyzed the activity of the streptogramin (...) components individually and in combination. The streptogramin A and B components in Synercid and NXL 103 exhibit synergistic antimicrobial activity against certain pathogenic bacteria. However, in transcription-coupled translation assays, only combinations that include dalfopristin, the streptogramin A component of Synercid, show synergy. Notably, the diethylaminoethylsulfonyl group in dalfopristin reduces its activity but is the basis for synergy in transcription-coupled translation assays before its

Full Text available with Trip Pro

2014 Antimicrobial Agents and Chemotherapy

76. Patients Response to Early Switch To Oral:Osteomyelitis Study

® Rifapentine Priftin® Linezolid* Zyvox® Quinopristin+Dalfopristin* Synercid® Bacitracin Baci-IM Chloramphenicol* Chloromycetin® Colistemetate Coly-Mycin® M & S Fosfomycin Monurol® Isoniazid Rifamate® Methenamine Hiprex®, Mandelamine® Metronidazol Flagyl® Mupirocin Bactroban® Nitrofurantoin Macrobid®, Macrodantin®, Furantoin® Nitrofurazone Furacin® Novobiocin Albamycin® Polymyxin B Aerospin® Spectinomycin T robicin® T rimethoprim Proloprim®, Trimpex® Colistin Cycloserine Capreomycin Ethionamide (...) Sulfasalazine®,Azulfidine® Sulfisoxazole T rimethoprim-Sulfamethoxazole Bactrim®, Septra®, Cofatrim®, Primsol® Sulfamethizole Thiosulfil Forte® Rifabutin Mycobutin® Rifampin Rifadin® Rifapentine Priftin® Linezolid* Zyvox® Quinopristin+Dalfopristin* Synercid® Bacitracin Baci-IM Chloramphenicol* Chloromycetin® Colistemetate Coly-Mycin® M & S Fosfomycin Monurol® Isoniazid Rifamate® Methenamine Hiprex®, Mandelamine® Metronidazol Flagyl® Mupirocin Bactroban® Nitrofurantoin Macrobid®, Macrodantin®, Furantoin®

2014 Clinical Trials

77. Dermabacter hominis: a usually daptomycin-resistant gram-positive organism infrequently isolated from human clinical samples (PubMed)

received antimicrobial treatment (ciprofloxacin, ceftriaxone plus vancomycin and amoxicillin/clavulanic acid). At least ten patients had several underlying diseases and conditions, and no direct mortality was observed in relation to the isolated organism. All isolates were susceptible to vancomycin, rifampin and linezolid. Resistance to other antibiotics varied: erythromycin (100%), clindamycin (78.5%), ciprofloxacin (21.4%) and gentamicin, quinupristin-dalfopristin, benzylpenicillin and imipenem 7.1

Full Text available with Trip Pro

2014 New Microbes and New Infections

78. Enterococcal Infections (Overview)

result in synergistic bactericidal activity against enterococci. The acquisition of vancomycin resistance by enterococci has seriously affected the treatment and infection control of these organisms. VRE, particularly E faecium strains, are frequently resistant to all antibiotics that are effective treatment for vancomycin-susceptible enterococci, which leaves clinicians treating VRE infections with limited therapeutic options. Newer antibiotics (eg, quinupristin-dalfopristin, linezolid, daptomycin (...) , tigecycline) with activity against many VRE strains have improved this situation, but resistance to these agents has already been described. A mutation (G2576U) in the domain V of the 23S rRNA is responsible for linezolid resistance, [ ] whereas resistance to quinupristin-dalfopristin may be the result of several mechanisms: modification of enzymes, active efflux, and target modification. Resistance of E faecalis and E faecium to daptomycin, a newer cyclic lipopeptide antibiotic that acts on the bacterial

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>